Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
The capital expansion program commenced in June 2022 and is expected to complete in 2024
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
This dense phase often resembles liquid droplets exhibiting higher protein density and weaker molecular motion than the surrounding medium.
Subscribe To Our Newsletter & Stay Updated
